VAB, which we developed and launched with Validus Pharmaceuticals, encourages and enables physician participation and communication through a variety of moderated comment and discussion tools within featured content pages. The first feature program is a four-part video series focusing on the unmet needs in Bipolar I. The presenters discuss the treatment of Bipolar I using the drug carbamazepine, and how carbamazepine evolved from discovery and clinical trials into the FDA-approved formulation, Equetro, that is used in clinical practice today.

Too often these individuals are defined by the media based solely on their most recent performances, and the public has no access to information about who they really are “off the field”.  So we’ve developed a proprietary Internet-based platform through which they can deliver their total message, build support for causes they support, and generate income directly from online media advertising, e-commerce, and the sale/license of original, documentary-quality film content.

We work closely with our clients, their agents and advisors, to help them take total control of their online brand in a way that will sustain their professional viability right now, and also into the next phases of their careers and lives.

Featured emerging scientific issues and clinical information are conveniently organized and updated on a weekly basis. OurCreatus.org offers an inside view of Amylin’s cutting-edge approaches to discovery, research and development and the scientists who are making it happen.

We’ve been working with them for two years as part of a multi-agency partnership to develop and manage the company’s relationships with key industry opinion leaders (prominent practicing and academic physicians that are heavily involved in scientific research, clinical trial investigation, and who speak and write extensively on developments in these disease areas).

The cornerstone of our program is a magnet web property known as “CREATUS” (the Latin for “to create”). It’s a members-only portal rich in scientific media and other resources, delivering breaking news, clinical information and the latest discovery research from every legitimate outlet around the globe – not just from Amylin. Unique in its non-promotional tone and democratic approach to inclusion of industry-wide content, we think it will become the new model for building strong physician relationships in the post-advertising era we’re living in today.